Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Net Cash Flow (2020 - 2025)

Foghorn Therapeutics has reported Net Cash Flow over the past 6 years, most recently at -$8.5 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$8.5 million for Q4 2025, down 280.31% from a year ago — trailing twelve months through Dec 2025 was $27.0 million (up 208.37% YoY), and the annual figure for FY2025 was $27.0 million, up 208.37%.
  • Net Cash Flow for Q4 2025 was -$8.5 million at Foghorn Therapeutics, down from $16.8 million in the prior quarter.
  • Over the last five years, Net Cash Flow for FHTX hit a ceiling of $112.5 million in Q1 2022 and a floor of -$152.4 million in Q2 2022.
  • Median Net Cash Flow over the past 5 years was $6.3 million (2023), compared with a mean of -$520100.0.
  • Peak annual rise in Net Cash Flow hit 745.28% in 2024, while the deepest fall reached 744.84% in 2024.
  • Foghorn Therapeutics' Net Cash Flow stood at $43.3 million in 2021, then tumbled by 181.8% to -$35.4 million in 2022, then skyrocketed by 128.32% to $10.0 million in 2023, then plummeted by 122.17% to -$2.2 million in 2024, then plummeted by 280.31% to -$8.5 million in 2025.
  • The last three reported values for Net Cash Flow were -$8.5 million (Q4 2025), $16.8 million (Q3 2025), and $13.1 million (Q2 2025) per Business Quant data.